Hiroshi Miyamoto, M.D., Ph.D.

Hiroshi Miyamoto, M.D., Ph.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 626
Rochester, NY 14642

Office: (585) 275-8748
Lab: (585) 275-1739
Administrative: (585) 275-3191
Fax: (585) 273-3637

Research Bio

Dr. Miyamoto's primary research interest includes molecular biology of steroid hormone receptors in genitourinary tumors. Specifically, he has been investigating the role of androgen receptor signals in the development and progression of bladder cancer. Epidemiological and clinical data indicate that men have a substantially higher risk of bladder cancer, and the underlying mechanisms of how androgens regulate bladder tumorigenesis and tumor outgrowth will offer explanations for this gender-specific difference in cancer incidence. He has also assessed the effects of new classes of androgen receptor antagonists on prostate cancer progression and has characterized novel androgen receptor co-regulators in prostate cancer cells.

Awards & Honors (Local)

Johns Hopkins Greenberg Bladder Cancer Research Award 2015 - 2016
Department of Defense Prostate Cancer Research Program Idea Development Award 2013 - Present
Clinical and Translational Science Institute (CTSI) - Laboratory Support Award (LSA) | University of Rochester Medical Center 2012
Department of Defense Prostate Cancer Research Program Physician Research Training Award 2009 - 2015
Department of Defense Breast Cancer Research Program Idea Development Award 2002 - 2005
CaPCURE Award 1997

Recent Journal Articles

Showing the 5 most recent journal articles. 156 available »

2016 Jul 18
Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, Netto GJ, Ishiguro H, Miyamoto H. "ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion." Oncotarget. 2016 Jul 18; Epub 2016 Jul 18.
2016 Jun 18
Kawahara T, Ide H, Kashiwagi E, El-Shishtawy KA, Li Y, Reis LO, Zheng Y, Miyamoto H. "Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth." Urologic oncology. 2016 Jun 18; Epub 2016 Jun 18.
2016 Jun 14
Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H. "Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer." Oncotarget. 2016 Jun 14; Epub 2016 Jun 14.
2016 Jun
Kawahara T, Miyamoto H, Ito H, Terao H, Kakizoe M, Kato Y, Ishiguro H, Uemura H, Yao M, Matsuzaki J. "Predicting the mineral composition of ureteral stone using non-contrast computed tomography." Urolithiasis. 2016 Jun; 44(3):231-9. Epub 2015 Oct 01.
2016 Jun
Kawahara T, Aljarah AK, Shareef HK, Inoue S, Ide H, Patterson JD, Kashiwagi E, Han B, Li Y, Zheng Y, Miyamoto H. "Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine." The Prostate. 2016 Jun; 76(8):744-56. Epub 2016 Feb 11.

Current Appointments

Associate Professor - Department of Pathology and Laboratory Medicine (SMD) - Primary
Associate Professor - Department of Urology (SMD)
Associate Professor - Cancer Center

Specialties

Anatomic Pathology - American Board of Pathology

Education

PhD | Urology | Yokohama City University School of Medicine2000
MD | Medicine | Yokohama City University School of Medicine1988

Post-Doctoral Training & Residency

Fellowship in Urological Pathology at Johns Hopkins University School of Medicine, Office of Registrar07/01/2008 - 06/30/2009
Residency in Pathology at University of Rochester Medical Center07/01/2005 - 06/30/2008
Residency in Urology at Yokohama City University Hospital06/02/1988 - 06/01/1990